Literature DB >> 16158923

Her-2/neu expression in breast cancer--A comparison of different diagnostic methods.

P Benöhr1, V Henkel, R Speer, U Vogel, K Sotlar, B Aydeniz, A Reiser, H Neubauer, K Tabiti, D Wallwiener, S E Clare, R Kurek.   

Abstract

BACKGROUND: Determination of Her-2/neu overexpression in breast cancer has previously been shown to be of prognostic significance. In this study, Her-2/neu expression in breast cancer was characterised by real-time PCR (RLT-PCR) based LightCycler-HER-2/neu DNA Quantification with immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH).
MATERIAL AND METHODS: Fifteen specimens of invasive breast cancer - whole tissue sections as well as microdissected tumour cells - were subjected to RLT-PCR. Additionally, IHC and FISH were performed.
RESULTS: Her-2/neu overexpression was detected by FISH and by real-time PCR in the same tumours. In contrast, IHC revealed discordant results.
CONCLUSION: Determination of Her-2/neu amplification by real-time PCR is a sensitive and specific method with some advantages over FISH. This method is simple and reliable and has the potential of categorizing those tumours with borderline Her-2/neu overexpression as determined by IHC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16158923

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Accurate breast cancer diagnosis through real-time PCR her-2 gene quantification using immunohistochemically-identified biopsies.

Authors:  Gretel Mendoza; Amelia Portillo; Jorge Olmos-Soto
Journal:  Oncol Lett       Date:  2012-10-22       Impact factor: 2.967

2.  The epidermal growth factor receptor family in breast cancer.

Authors:  Angelos K Koutras; T R Jeffry Evans
Journal:  Onco Targets Ther       Date:  2008-09-01       Impact factor: 4.147

3.  Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer.

Authors:  Andreea Nistor; Peter H Watson; Norman Pettigrew; Karim Tabiti; Angelika Dawson; Yvonne Myal
Journal:  BMC Clin Pathol       Date:  2006-01-18

Review 4.  Quantification of HER family receptors in breast cancer.

Authors:  Paolo Nuciforo; Nina Radosevic-Robin; Tony Ng; Maurizio Scaltriti
Journal:  Breast Cancer Res       Date:  2015-04-09       Impact factor: 6.466

Review 5.  Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions.

Authors:  Heng-Zhou Lai; Jie-Rong Han; Xi Fu; Yi-Feng Ren; Zhuo-Hong Li; Feng-Ming You
Journal:  Cancers (Basel)       Date:  2022-08-03       Impact factor: 6.575

6.  In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.

Authors:  Maria Vassilakopoulou; Taiwo Togun; Urania Dafni; Huan Cheng; Jennifer Bordeaux; Veronique M Neumeister; Mattheos Bobos; George Pentheroudakis; Dimosthenis V Skarlos; Dimitrios Pectasides; Vassiliki Kotoula; George Fountzilas; David L Rimm; Amanda Psyrri
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

7.  Fluorescent in Situ Hybridization and Real-Time Quantitative Polymerase Chain Reaction to Evaluate HER-2/neu Status in Breast Cancer.

Authors:  Fatemeh Homaei Shandiz; Azar Fani; Sepideh Shakeri; Maryam Sheikhi; Abouzar Ramezani Farkhani; Arezoo Shajiei; Hossein Ayatollahi
Journal:  Iran J Pathol       Date:  2016-08-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.